UK markets closed

Celyad Oncology SA (CYADB.XC)

Cboe UK - Cboe UK Real-time price. Currency in EUR
Add to watchlist
6.67+6.02 (+919.88%)
At close: 09:34AM BST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
44
0
0
5
6
Cost of revenue
44
0
0
0
0
Gross profit
0
0
0
5
6
Operating expenses
Research development
10,540
18,928
20,773
21,522
25,232
Selling general and administrative
7,757
10,337
9,665
9,315
8,725
Total operating expenses
8,803
20,263
26,909
26,220
29,379
Operating income or loss
-8,803
-20,263
-26,909
-26,215
-29,373
Interest expense
91
197
255
434
343
Total other income/expenses net
-
-20,422
523
9,228
495
Income before tax
-30,554
-40,870
-26,502
-17,204
-28,640
Income tax expense
65
65
10
0
-8
Income from continuing operations
-30,619
-40,935
-26,512
-17,204
-28,632
Net income
-30,619
-40,935
-26,512
-17,204
-28,632
Net income available to common shareholders
-30,619
-40,935
-26,512
-17,204
-28,632
Basic EPS
-1.36
-1.81
-1.70
-1.23
-2.29
Diluted EPS
-1.36
-1.81
-1.70
-1.23
-2.29
Basic average shares
22,558
22,594
15,604
13,942
12,523
Diluted average shares
22,558
22,594
15,604
13,942
12,523